Nesci A, Ruggieri V, Manilla V, Spinelli I, Santoro L, Di Giorgio A
Int J Mol Sci. 2024; 25(23).
PMID: 39684569
PMC: 11640898.
DOI: 10.3390/ijms252312859.
Alotay A
Cureus. 2024; 16(7):e65869.
PMID: 39219865
PMC: 11364363.
DOI: 10.7759/cureus.65869.
Muric M, Nikolic M, Todorovic A, Jakovljevic V, Vucicevic K
Biomolecules. 2024; 14(8).
PMID: 39199344
PMC: 11352257.
DOI: 10.3390/biom14080956.
Portela C, Gautier L, Zermatten M, Fraga M, Moradpour D, Calderara D
JHEP Rep. 2024; 6(8):101116.
PMID: 39100819
PMC: 11296254.
DOI: 10.1016/j.jhepr.2024.101116.
Gao J, Lan T, Kostallari E, Guo Y, Lai E, Guillot A
J Hepatol. 2024; 81(3):543-561.
PMID: 38763358
PMC: 11906189.
DOI: 10.1016/j.jhep.2024.05.014.
Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2-ERK 1/2 pathway.
Maeda K, Kuriyama N, Noguchi D, Ito T, Gyoten K, Hayasaki A
PLoS One. 2024; 19(5):e0292628.
PMID: 38748746
PMC: 11095713.
DOI: 10.1371/journal.pone.0292628.
A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban.
Guo Y, Dong S, Li M, Tao Y, Lv J, Liu C
BMC Gastroenterol. 2024; 24(1):161.
PMID: 38741060
PMC: 11092107.
DOI: 10.1186/s12876-024-03253-4.
Combining T1rho and advanced diffusion MRI for noninvasively staging liver fibrosis: an experimental study in rats.
Guo Y, Guo T, Huang C, Sun P, Wu Z, Jin Z
Abdom Radiol (NY). 2024; 49(6):1881-1891.
PMID: 38607572
PMC: 11213740.
DOI: 10.1007/s00261-024-04327-3.
Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.
Patel M, Hunt C, VanWagner L
Gastroenterol Hepatol (N Y). 2024; 19(11):662-669.
PMID: 38405225
PMC: 10882863.
The implication of neutrophil extracellular traps in nonalcoholic fatty liver disease.
Fa P, Ke B, Dupre A, Tsung A, Zhang H
Front Immunol. 2023; 14:1292679.
PMID: 38022519
PMC: 10652891.
DOI: 10.3389/fimmu.2023.1292679.
Mechanobiology of portal hypertension.
Felli E, Selicean S, Guixe-Muntet S, Wang C, Bosch J, Berzigotti A
JHEP Rep. 2023; 5(11):100869.
PMID: 37841641
PMC: 10568428.
DOI: 10.1016/j.jhepr.2023.100869.
Compensated liver cirrhosis: Natural course and disease-modifying strategies.
Kumar R, Kumar S, Prakash S
World J Methodol. 2023; 13(4):179-193.
PMID: 37771878
PMC: 10523240.
DOI: 10.5662/wjm.v13.i4.179.
mTOR-dependent loss of PON1 secretion and antiphospholipid autoantibody production underlie autoimmunity-mediated cirrhosis in transaldolase deficiency.
Winans T, Oaks Z, Choudhary G, Patel A, Huang N, Faludi T
J Autoimmun. 2023; 140:103112.
PMID: 37742509
PMC: 10957505.
DOI: 10.1016/j.jaut.2023.103112.
Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis.
Giuli L, Pallozzi M, Venturini G, Gasbarrini A, Ponziani F, Santopaolo F
Int J Mol Sci. 2023; 24(16).
PMID: 37628933
PMC: 10454315.
DOI: 10.3390/ijms241612754.
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications.
Airola C, Pallozzi M, Cerrito L, Santopaolo F, Stella L, Gasbarrini A
Cells. 2023; 12(13).
PMID: 37443746
PMC: 10341358.
DOI: 10.3390/cells12131712.
Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation.
Falco L, Tessitore V, Ciccarelli G, Malvezzi M, DAndrea A, Imbalzano E
Antioxidants (Basel). 2023; 12(6).
PMID: 37371915
PMC: 10294911.
DOI: 10.3390/antiox12061185.
Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?.
Protopapas A, Savopoulos C, Skoura L, Goulis I
Dig Dis Sci. 2023; 68(6):2237-2246.
PMID: 36961672
PMC: 10188576.
DOI: 10.1007/s10620-023-07858-9.
Emerging Therapeutic Targets for Portal Hypertension.
Felli E, Nulan Y, Selicean S, Wang C, Gracia-Sancho J, Bosch J
Curr Hepatol Rep. 2023; 22(1):51-66.
PMID: 36908849
PMC: 9988810.
DOI: 10.1007/s11901-023-00598-4.
Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.
Bitto N, Ghigliazza G, Lavorato S, Caputo C, La Mura V
J Clin Med. 2023; 12(3).
PMID: 36769582
PMC: 9917703.
DOI: 10.3390/jcm12030934.
Current and investigational drugs in early clinical development for portal hypertension.
Sakiani S, Heller T, Koh C
Front Med (Lausanne). 2022; 9:974182.
PMID: 36300180
PMC: 9589453.
DOI: 10.3389/fmed.2022.974182.
